Product Information
Registration Status: ActiveSIN07944P
DBL VINBLASTINE INJECTION is approved to be sold in Singapore with effective from 1994-09-12. It is marketed by HOSPIRA SINGAPORE PTE LTD, with the registration number of SIN07944P.
This product contains Vinblastine 1mg/ml in the form of INJECTION. It is approved for INTRAVENOUS use.
This product is manufactured by HOSPIRA AUSTRALIA PTY LTD in AUSTRALIA.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Indication
For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.
Mechanism of Action
The antitumor activity of vinblastine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinblastine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death.
Toxicity
Oral, mouse: LD50 = 423 mg/kg; Oral, rat: LD50 = 305 mg/kg.
Active Ingredient/Synonyms
Vinblastin | Vinblastina | Vinblastine | Vinblastinum | Vincaleukoblastine | Vinblastine |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.